Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study.

O'Malley, Padraic G; Nguyen, Daniel P.; Al Hussein Al Awamlh, Bashir; Wu, Guojiao; Thompson, Ian M; Sanda, Martin; Rubin, Mark Andrew; Wei, John T; Lee, Richard; Christos, Paul; Barbieri, Christopher; Scherr, Douglas S (2017). Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. The journal of urology, 198(1), pp. 42-49. Elsevier 10.1016/j.juro.2017.01.058

[img] Text
1-s2.0-S0022534717300848-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

PURPOSE To our knowledge it is unknown whether urinary biomarkers for prostate cancer have added utility to clinical risk calculators in different racial groups. We examined the utility of urinary biomarkers added to clinical risk calculators for predicting prostate cancer in African American and nonAfrican American men. MATERIALS AND METHODS Demographics, PCPT (Prostate Cancer Prevention Trial) risk scores, data on the biomarkers data PCA3 (prostate cancer antigen 3) and T2ERG (transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog gene fusion), and biopsy pathology features were prospectively collected on 718 men as part of EDRN (Early Detection Research Network). Utility was determined by generating ROC curves and comparing AUC values for the baseline multivariable PCPT model and for models containing biomarker scores. RESULTS PCA3 and T2ERG added utility for the prediction of prostate cancer and clinically significant prostate cancer when combined with the PCPT Risk Calculator. This utility was seen in nonAfrican American men only for PCA3 (AUC 0.64 increased to 0.75 for prostate cancer and to 0.69-0.77 for clinically significant prostate cancer, both p <0.001) and for T2ERG (AUC 0.64-0.74 for prostate cancer, p <0.001, and 0.69-0.73 for clinically significant prostate cancer, p = 0.029). African American men did not have an added benefit with the addition of biomarkers, including PCA3 (AUC 0.75-0.77, p = 0.64, and 0.65-0.66, p = 0.74) and T2ERG (AUC 0.75-0.74, p = 0.74, and 0.65-0.64, p = 0.88), for prostate cancer and clinically significant prostate cancer, respectively. Limitations include the small number of African American men (72). The post hoc subgroup analysis nature of the study limited findings to being hypothesis generating. CONCLUSIONS As novel biomarkers are discovered, clinical utility should be established across demographically diverse cohorts.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Nguyen, Daniel Truong Phat and Rubin, Mark Andrew


600 Technology > 610 Medicine & health
500 Science
500 Science > 570 Life sciences; biology








Marla Rittiner

Date Deposited:

02 Feb 2018 12:53

Last Modified:

23 Oct 2019 09:30

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

African Americans biomarkers gene fusion human prostate cancer antigen 3 prostatic neoplasms tumor





Actions (login required)

Edit item Edit item
Provide Feedback